Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: antibody-drug conjugates - Genentech

Drug Profile

Research programme: antibody-drug conjugates - Genentech

Alternative Names: 11D10.1.14; 11D10.1.14 ADC; 11D10.1.14-auristatin conjugate; 3A5-VC-MMAE; 3A5-VC-MMAF; 3A5-VC-monomethylauristatin-E; 3A5-VC-monomethylauristatin-F; Anti-CA-125 ADC; Anti-CA-125 antibody drug conjugate; Anti-MUC16 ADC; Drug-conjugated 11D10; Drug-conjugated 3A5

Latest Information Update: 04 Nov 2017

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Genentech
  • Developer Genentech; Seattle Genetics
  • Class Auristatins; Immunotoxins; Monoclonal antibodies
  • Mechanism of Action Apoptosis stimulants; Mitosis inhibitors; Tubulin inhibitors; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral, Injection)
  • 16 Apr 2016 Pharmacodynamics data from a preclinical study in Cancer presented at the 107th Annual Meeting of the American Association for Cancer Research (AACR-2016)
  • 03 Aug 2010 Seattle Genetics and Genentech expand their antibody-drug conjugate collaborative agreement
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top